Pyridoxine (vitamin B 6 ) protects neurons against neurotoxicity. An excessive release of glutamate is widely considered to be one of the molecular mechanisms of neuronal damage in several neurological diseases. We investigated whether pyridoxine affected glutamate release in rat cerebral cortex nerve terminals (synaptosomes). Pyridoxine inhibited the release of glutamate that was evoked by exposing synaptosomes to the K ϩ channel blocker 4-aminopyridine (4-AP), and this phenomenon was concentration-dependent. Inhibition of glutamate release by pyridoxine was prevented by the vesicular transporter inhibitor bafilomycin A1, or by chelating intraterminal Ca 2ϩ , but was insensitive to DL-threo-␤-benzyl-oxyaspartate, a glutamate transporter inhibitor. Pyridoxine did not alter the resting synaptosomal membrane potential or 4-AP-mediated depolarization. Examination of the effect of pyridoxine on cytosolic [Ca 2ϩ ] revealed that diminution of glutamate release could be attributed to a reduction in voltage-dependent Ca 2ϩ influx. Consistent with this, the pyridoxine-mediated inhibition of glutamate release was completely prevented by blocking the Nand P/Q-type Ca 2ϩ channels, but not by blocking intracellular Ca 2ϩ release or Na ϩ /Ca 2ϩ exchange. Furthermore, the pyridoxine effect on 4-AP-evoked glutamate release was abolished by the protein kinase C (PKC) inhibitors bisindolylmaleimide I (GF109203X) or bisindolylmaleimide IX (Ro318220), and pyridoxine significantly decreased the 4-AP-induced phosphorylation of PKC, PKC␣, and myristoylated alanine-rich C kinase substrate. Together, these results suggest that pyridoxine inhibits glutamate release from rat cortical synaptosomes, through the suppression of presynaptic voltage-dependent Ca 2ϩ entry and PKC activity.
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Vitamin B 6 is one of the most important micronutrients that we obtain from foods. It helps maintain normal brain functions; therefore, vitamin B 6 deficiency leads to a range of neurological dysfunctions, such as nervousness, depression, seizures, and severe central neuropathy (Baxter, 2003) . Several in vitro and in vivo experimental studies have demonstrated that vitamin B 6 exerts neural protective effects. It has been shown, for example, that vitamin B 6 attenuates glutamate-induced neurotoxicity (Kaneda et al., 1997) , and protects against ischemia-or glucose-deprivation-induced neuronal death and glutamic-acid-induced seizures (Geng et al., 1997; Yamashima et al., 2001; Wang et al., 2002; Dakshinamurti et al., 2003; Hwang et al., 2007) . Furthermore, vitamin B 6 has been reported to promote the neuronal survival and improve cognitive function like memory (Geng et al., 1995; Araujo et al., 2008) . These findings suggest that vitamin B 6 is not only required for the normal brain function, but also plays a protective role against excitotoxicity to the brain. The mechanisms underlying the neuroprotective effects of vitamin B 6 are not fully clarified, however.
In the brain, glutamate is a major excitatory neurotransmitter that plays an important role in many functions such as synaptic plasticity, learning, and memory (Greenamyre and Porter, 1994; Danbolt, 2001) . Besides its physiological role, glutamate is also a potent neurotoxin and high levels in the synaptic cleft may lead to excitotoxicity. This process has been proposed to be involved in a number of neuropathological conditions, ranging from acute insults such as stroke, epileptic seizures, traumatic brain and spinal cord injury, to chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (Obrenovitch and Urenjak, 1997; Meldrum, 2000; Raiteri et al., 2004) . Therefore, a reduction in glutamate release from nerve terminals is considered to be a potentially important mechanism for neuroprotective actions.
Considering that excessive release of glutamate is a critical factor in the neuropathology of acute and chronic brain disorders, it is possible that the neuroprotective effect of vitamin B 6 in experimental models is associated with a decrease in glutamate release. To address this issue, in the present study, we used isolated nerve terminals (synaptosomes) purified from the rat cerebral cortex to investigate the influence of pyridoxine (vitamin B 6 ) on glutamate release. The isolated presynaptic terminal represents a model system for investigating directly the molecular mechanisms underlying presynaptic phenomena. Specifically, this preparation is capable of accumulating, storing, and releasing neurotransmitters, and is devoid of functional glial and nerve cell body elements that might obfuscate interpretation because of modulatory loci at non-neuronal, postsynaptic, or network levels (Dunkley et al., 1986) . The experiments were performed with synaptosomes by monitoring the effects of pyridoxine on the release of endogenous glutamate, synaptosomal plasma membrane potential, and downstream activation of voltagedependent Ca 2ϩ channels (VDCCs). In addition, in view of the demonstrated role of protein kinase C (PKC) in presynaptic modulation (Coffey et al., 1993; Vaughan et al., 1998) , this study also examined whether this signaling pathway was involved in the regulation of pyridoxine on glutamate release.
Materials and Methods
Materials. 3Ј,3Ј,3Ј-Dipropylthiadicarbocyanine iodide [DiSC 3 (5)] and fura-2-acetoxymethyl ester (Fura-2-AM) were obtained from Invitrogen (Carlsbad, CA). Bafilomycin A1, -conotoxin (-CgTX) GVIA, -conotoxin (CgTX) MVIIC, dantrolene, DL-threo-␤-benzyl-oxyaspartate (DL-TBOA), and GF109203X were obtained from Tocris Bioscience (Bristol, UK). Pyridoxine, pyridoxal, pyridoxal phosphate (PLP), 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid-acetoxymethyl ester (BAPTA-AM), -agatoxin (-AgTX) IVA, SDS, and all other reagents were obtained from Sigma Chemical (Poole, Dorset, UK).
Animals. Adult male Sprague-Dawley rats (250 -300 g) were used in these studies. All animal procedures were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals, and were approved by the Fu Jen Institutional Animal Care and Utilization Committee.
Synaptosomal Preparation. Synaptosomes were prepared as described previously (Wang and Sihra, 2004) . In brief, the cerebral cortex from 2-month-old male Sprague-Dawley rats was isolated and homogenized in a medium that contained 320 mM sucrose, pH 7.4. The homogenate was spun for 2 min at 3000g (5000 rpm in a JA 25.5 rotor; Beckman Coulter, Inc., Fullerton, CA) at 4°C, and the supernatant was spun again at 14,500g (11,000 rpm in a JA 25.5 rotor) for 12 min. The pellet was gently resuspended in 8 ml of 320 mM sucrose, pH 7.4. Two milliliters of this synaptosomal suspension was added to 3 ml of Percoll discontinuous gradients that contained 320 mM sucrose, 1 mM EDTA, 0.25 mM DL-dithiothreitol, and 3, 10, and 23% Percoll, pH 7.4. The gradients were centrifuged at 32,500g (16,500 rpm in a JA 20.5 rotor) for 7 min at 4°C. Synaptosomes placed between the 10 and 23% Percoll bands were collected and diluted in a final volume of 30 ml of HEPES buffer medium (HBM) that consisted of 140 mM NaCl, 5 mM KCl, 5 mM NaHCO 3 , 1 mM MgCl 2 ⅐6H 2 O, 1.2 mM Na 2 HPO 4 , 10 mM glucose, and 10 mM HEPES, pH 7.4, before centrifugation at 27,000g (15,000 rpm in a JA 25.5) for 10 min. The pellets thus formed were resuspended in 3 ml of HBM, and the protein content was determined by use of a Bradford Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA), based on the method of Bradford (1976) , with BSA as a standard. One-half milligram of synaptosomal suspension was diluted in 10 ml of HBM and spun at 3000g (5000 rpm in a JA 20.1 rotor) for 10 min. The supernatants were discarded, and the synaptosomal pellets were stored on ice and used within 4 to 6 h.
Glutamate Release. Glutamate release from purified cerebrocortical synaptosomes was monitored online, with an assay that used exogenous glutamate dehydrogenase (GDH) and NADP ϩ to couple the oxidative deamination of the released glutamate to the generation of NADPH detected fluorometrically (Nicholls, 1993) . Synaptosomal pellets were resuspended in HBM that contained 16 M BSA and incubated in a stirred and thermostatted cuvette maintained at 37°C in a PerkinElmer LS-50B spectrofluorimeter (PerkinElmer Life and Analytical Sciences, Waltham, MA). NADP ϩ (2 mM), GDH (50 units/ml), and CaCl 2 (1 mM) were added after 3 min. In experiments that investigated Ca 2ϩ -independent efflux of glutamate, EGTA (200 M) was added in place of CaCl 2 . Other additions before depolarization were made as described in the figure legends. After a further 10 min of incubation, 4-AP (1 mM), or KCl (15 mM) was added to stimulate glutamate release. Glutamate release was monitored by measuring the increase of fluorescence (excitation and emission wavelengths of 340 and 460 nm, respectively) caused by NADPH being produced by oxidative deamination of released glutamate by GDH. Data were accumulated at 2-s intervals. A standard of exogenous glutamate (5 nmol) was added at the end of each experiment, and the fluorescence response used to calculate released glutamate was expressed as nanomoles of glutamate per milligram of synaptosomal protein (nmol/mg). Values quoted in the text and expressed in bar graphs represent levels of glutamate cumulatively released after 5 min of depolarization.
Styryl Dye Release Assay. Synaptic vesicle fusion with the plasma membrane was measured by use of release of the fluorescent dye FM1-43, as described previously (Baldwin et al., 2003) . In brief, synaptosomes (0.5 mg/ml) were incubated in HBM with 1.2 mM CaCl 2 for 2 min at 37°C in a stirred test tube. FM1-43 (100 M) was added 1 min before stimulation with 30 mM KCl. After 3 min of stimulation to load FM1-43, synaptosomes were washed twice in HBM that contained 1.2 mM CaCl 2 and 1 mg/ml BSA to remove noninternalized FM1-43. Synaptosomes were then resuspended in 2 ml of HBM (plus 1.2 mM Ca 2ϩ ), and incubated in a stirred and thermostatted cuvette maintained at 37°C in a PerkinElmer LS-50B spectrofluorimeter (PerkinElmer Life and Analytical Sciences). Release of accumulated FM1-43 was induced by the addition of 1 mM 4-AP, and measured as the decrease in fluorescence upon release of the dye into solution (excitation 488 nm, emission 540 nm). Data points were obtained at 2.2-s intervals, and data were presented as the Ca 2ϩ -dependent decrease in FM1-43 fluorescence. Any drugs were added after the dye-loading procedure, and the synaptosomes were preincubated with pyridoxine for 10 min before depolarization with 4-AP.
Synaptosomal Plasma Membrane Potential. The synaptosomal membrane potential can be monitored by positively charged, membrane-potential-sensitive carbocyanine dyes such as DiSC 3 (5). Synaptosomes were preincubated and resuspended as described for the glutamate release experiments. After 3 min of incubation, 5 M DiSC 3 (5) was added and allowed to equilibrate before the addition of CaCl 2 (1 mM) after 4 min of incubation. 4-AP (1 mM) was added to depolarize the synaptosomes at 10 min, and DiSC 3 (5) fluorescence Cytosolic-Free Ca 2؉ Concentration. Cytosolic-free Ca 2ϩ concentration ([Ca 2ϩ ] C ) was measured by use of the Ca 2ϩ indicator Fura-2-AM. Synaptosomes (0.5 mg/ml) were preincubated in HBM with 16 M BSA in the presence of 5 M Fura-2-AM and 0.1 mM CaCl 2 , for 30 min at 37°C in a stirred test tube. After Fura-2-AM loading, synaptosomes were centrifuged in a microcentrifuge for 30 s at 3000g (5000 rpm). The synaptosomal pellets were resuspended in HBM with BSA, and the synaptosomal suspension was stirred in a thermostatted cuvette in a PerkinElmer LS-50B spectrofluorimeter (PerkinElmer Life and Analytical Sciences). CaCl 2 (1 mM) was added after 3 min and further additions were made after an additional 10 min. Fluorescence data were accumulated at excitation wavelengths of 340 and 380 nm (emission wavelength, 505 nm) at 7.5-s intervals. Calibration procedures were performed as described previously (Sihra et al., 1992) , using 0.1% SDS to obtain the maximal fluorescence with Fura-2 saturation with Ca 2ϩ , followed by 10 mM EGTA (Tris-buffered) to obtain minimum fluorescence in the absence of any Fura-2/Ca 2ϩ complex. [Ca 2ϩ ] C was calculated by use of equations described previously (Grynkiewicz et al., 1985) .
Western Blotting. Synaptosomes (0.5 mg protein/ml) from control and drug-treated groups were lysed in ice-cold Tris-HCl buffer solution, pH 7.5, that contained 20 mM Tris-HCl, 1% Triton, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM phenylmethanesulfonyl fluoride, 1 mM sodium orthovanadate, and 1 g/ml leupeptin. The lysates were sonicated for 10 s and then centrifuged at 13,000g at 4°C for 10 min. Equal amounts of samples were separated by electrophoresis on 7.5% SDS-polyacrylamide gel electrophoresis, and then transferred to nitrocellulose membranes. The membranes were blocked with Tris-buffered saline that contained 5% low-fat milk and incubated with the following primary polyclonal antibodies: phospho-PKC (pan) (to detect PKC-␣, -␤ I , -␤ II , -, -ε, -, and -␦, phosphorylated at a carboxyl-terminal residue homologous to Ser-660 of PKC-␤ II ), 1:3000 (Novus Biologicals Inc., Littleton, CO); phospho-PKC␣, 1:4000; and phospho-myristoylated alanine-rich C kinase substrate (MARCKS), 1:1000. After incubation with appropriate peroxidase-conjugated donkey anti-rabbit IgG secondary antibodies (1:3000), protein bands were detected by use of the ECL chemiluminescence system (GE Healthcare, Little Chalfont, Buckinghamshire, UK). An aliquot of samples was loaded and probed with anti-␤-actin antibody for detection of ␤-actin as a loading control. Films were scanned by use of a scanner and the level of phosphorylation was assessed by band density, which was quantified by densitometry.
Data Analysis. Cumulative data were analyzed in Lotus 1-2-3 and MicroCal Origin (OriginLab Corp, Northampton, MA). Data are expressed as mean Ϯ S.E.M. To test the significance of the effect of a drug versus control, a two-tailed Student's t test was used. When an additional comparison was required (such as whether a second treatment influenced the action of pyridoxine), a one-way repeatedmeasures analysis of variance (ANOVA) was computed. P Ͻ 0.05 was considered to represent a significant difference.
Results
Pyridoxine Inhibits 4-AP-Evoked Glutamate Release in Cerebrocortical Nerve Terminals. To investigate the influence of pyridoxine on glutamate release, isolated nerve terminals were depolarized with the K ϩ -channel blocker 4-AP. 4-AP destabilizes the membrane potential and is thought to cause repetitive spontaneous Na ϩ -channel-dependent depolarization that closely approximates in vivo depolarization of the synaptic terminal, which leads to the activation of VDCCs and neurotransmitter release (Nicholls, 1998) . In synaptosomes incubated in the presence of 1 mM CaCl 2 , 4-AP evoked a glutamate release of 7.7 Ϯ 0.1 nmol/mg/5 min. Application of pyridoxine (5 M) produced an inhibition of 4-AP-evoked glutamate release to 3.9 Ϯ 0.1 nmol/mg/5 min (n ϭ 6; P Ͻ 0.01), without altering the basal release of glutamate (Fig. 1A) . The pyridoxine-induced inhibition of 4-AP-evoked glutamate release was concentration-dependent, with an IC 50 value derived from a dose-response curve of approximately 4.5 M (Fig. 1B) . Given the robust repression of evoked glutamate release that was seen with 5 M pyridoxine, this concentration of pyridoxine was used in subsequent experiments to evaluate the mechanisms that underlie the ability of pyridoxine to reduce glutamate release. whether the inhibition of 4-AP-evoked glutamate release by pyridoxine was mediated by an effect on exocytotic vesicular release, or on Ca 2ϩ -independent release attributable to cytosolic efflux via reversal of the glutamate transporter (Nicholls et al., 1987) . First, the Ca 2ϩ -independent glutamate efflux was measured by depolarizing the synaptosomes with 1 mM 4-AP in extracellular Ca 2ϩ -free solution that contained 50 M BAPTA-AM, a cell-permeable Ca 2ϩ chelator. Under these conditions, the release of glutamate evoked by 4-AP was 1.3 Ϯ 0.2 nmol/mg/5 min. This Ca 2ϩ -independent release evoked by 4-AP was, however, not affected by 5 M pyridoxine (1.2 Ϯ 0.1 nmol/mg/5 min) (n ϭ 6; Fig. 2A ). Second, we investigated the action of pyridoxine in the presence of DL-TBOA, a nonselective inhibitor of all excitatory amino acid transporter subtypes, or bafilomycin A1, which causes the depletion of glutamate in synaptic vesicles. In the presence of DL-TBOA, although 4-AP-evoked glutamate release (7.2 Ϯ 0.1 nmol/mg/5 min) was increased by the inhibitor (because of inhibition of reuptake of released glutamate) (11.3 Ϯ 0.2 nmol/mg/5 min; P Ͻ 0.01), pyridoxine continued to reduce significantly 4-AP-induced release of glutamate (9.1 Ϯ 0.3 nmol/mg/5 min) (n ϭ 6; P Ͻ 0.05; Fig. 2 , B and D). In contrast to DL-TBOA, bafilomycin A1 (0.1 M) reduced control 1 mM 4-AP-evoked glutamate release from 7.7 Ϯ 0.1 to 1.8 Ϯ 0.2 nmol/mg/5 min (P Ͻ 0.01), and completely prevented the inhibitory effect of pyridoxine (5 M) on 4-AP-evoked glutamate release (1.7 Ϯ 0.1 nmol/mg/5 min; n ϭ 7; Fig. 2C ). In the presence of bafilomycin A1, therefore, pyridoxine induced a statistically insignificant inhibition (P Ͼ 0.05; one-way repeated-measures ANOVA; Fig. 2D ).
Inhibition of 4-AP-Evoked Glutamate Release by
Furthermore, we examined the effect of pyridoxine on FM1-43 release. FM1-43 is a lipophilic but membrane-impermeable fluorescent styryl dye. When the styryl dye FM1-43 reversibly partitions into the outer leaflet of exposed plasma membrane, its fluorescence increases. By endocytosis, FM1-43 dye can be taken up into the synaptic vesicles, and during subsequent exocytosis, is lost to the extracellular medium, accompanied by a decrease in fluorescence (Baldwin et al., 2003) . In Fig. 2E , 4-AP (1 mM) caused a decrease in FM1-43 fluorescence in the presence of CaCl 2 . It is noteworthy that this 4-AP-evoked Ca 2ϩ -dependent decrease in FM1-43 fluorescence was also significantly inhibited by pyridoxine (5 M) (n ϭ 5; P Ͻ 0.01).
Pyridoxine Does Not Change the Synaptosomal Membrane Potential but Reduces Depolarization-Induced Ca 2؉ Influx. To further understand the mechanism responsible for the pyridoxine-mediated inhibition of glutamate release, we used a membrane-potential-sensitive dye, DiSC 3 (5), to determine the effect of pyridoxine on the synaptosomal plasma membrane potential. DiSC 3 (5) is a positively charged carbocyanine that accumulates in polarized synaptosomes that are negatively charged on the inside. At high concentrations, the dye molecules accumulate and the fluorescence is quenched. Upon depolarization, the dye moves out and hence the fluorescence increases. As shown in Fig.  3A , 4-AP (1 mM) caused an increase in DiSC 3 (5) fluorescence of 6.57 Ϯ 0.18 fluorescence units/5 min. Preincubation of synaptosomes with pyridoxine (5 M) for 10 min before 4-AP addition did not alter the resting membrane potential, and produced no significant change in the 4-AP-mediated increase in DiSC 3 (5) fluorescence (6.63 Ϯ 0.29 fluorescence units/5 min; P Ͼ 0.05; n ϭ 8). This indicates that the observed inhibition of evoked glutamate release by pyridoxine is unlikely to have been caused by a hyperpolarizing effect of the drug on the synaptosomal plasma membrane potential, or attenuation of the depolarization produced by 4-AP. Confirmation that the pyridoxine effect did not impinge on synaptosomal excitability was obtained with experiments using high external [K ϩ ]-mediated depolarization. Elevated extracellular KCl depolarizes the plasma membrane by shifting the K ϩ equilibrium potential above the threshold potential for activation of voltage-dependent ion channels. Although Na ϩ channels are inactivated under these conditions, VDCCs are activated nonetheless to mediate Ca 2ϩ entry, which supports neurotransmitter release (Barrie et al., 1991) . Addition of 15 mM KCl evoked controlled glutamate release of 9.5 Ϯ 0.1 nmol/mg/5 min, which was reduced to 4.9 Ϯ 0.4 nmol/ mg/5 min in the presence of 5 M pyridoxine (n ϭ 7; P Ͻ 0.01) (Fig. 3B) . This phenomenon was concentration-dependent, with an IC 50 value derived from a dose-response curve of approximately 4.2 M (Fig. 3C) .
Downstream of membrane depolarization, presynaptic inhibition of neurotransmitter release can be mediated by a reduction of Ca 2ϩ influx into nerve terminals or by direct interference with the neurotransmitter exocytotic process. To investigate the first of those possibilities, we used the Ca Involvement of Presynaptic N-and P/Q-type Ca
2؉
Channels in Pyridoxine-Mediated Inhibition of Glutamate Release. In the adult rat cerebrocortical nerve terminal preparation, the release of glutamate evoked by depolarization relies on the entry of Ca 2ϩ through N-and P/Q-type Ca 2ϩ channels (Vá zquez and Sá nchez-Prieto, 1997; Millán and Sá nchez-Prieto, 2002) . Therefore, we sought to establish which type of Ca 2ϩ channel was involved in the pyridoxinemediated inhibition of 4-AP-evoked glutamate release, by performing occlusion experiments with the Ca 2ϩ channel antagonist -conotoxin (CgTX) GVIA and -agatoxin (AgTX) IVA, which selectively block N-and P/Q-type Ca 2ϩ channels, respectively. Application of 2 M -CgTX GVIA or 200 nM -AgTX IVA reduced 4-AP-evoked glutamate release from 7.6 Ϯ 0.4 to 4.6 Ϯ 0.1 or 3.9 Ϯ 0.3 nmol/mg/5 min (P Ͻ 0.01; Fig. 5B ), respectively. In the presence of -CgTX GVIA alone, 5 M pyridoxine reduced glutamate release by a further 23.9% (3.5 Ϯ 0.2 nmol/mg/5 min; n ϭ 5; P Ͻ 0.05). In the presence of -AgTX IVA, 5 M pyridoxine still effectively reduced release by a further 30.8% (2.7 Ϯ 0.2 nmol/mg/5 min; n ϭ 5; P Ͻ 0.05). After the combined application of -CgTX GVIA and -AgTX IVA, when glutamate release was reduced to 3.1 Ϯ 0.2 nmol/mg/5 min (n ϭ 7; P Ͻ 0.01), 5 M pyridoxine caused a marginal further decrease to 2.8 Ϯ 0.1 nmol/mg/5 min. This represented a statistically insignificant change in 4-AP-evoked glutamate release that resulted from pyridoxine in the presence of N-and P/Q-type VDCC block (n ϭ 7; P Ͻ 0.05; Fig. 5, A and B) . Likewise, we found that 1 M -CgTX -independent release was assayed by omitting CaCl 2 and adding 50 M BAPTA-AM 10 min before depolarization, and was evoked by 1 mM 4-AP under control conditions, or in the presence of 5 M pyridoxine added 10 min before the addition of 4-AP. B and C, glutamate release was evoked by 1 mM 4-AP in the absence (control) or presence of 5 M pyridoxine, 10 M DL-TBOA, 10 M DL-TBOA ϩ 5 M pyridoxine, 0.1 M bafilomycin A1, or 0.1 M bafilomycin A1 ϩ 5 M pyridoxine. Pyridoxine was added 10 min before depolarization and DL-TBOA or bafilomycin A1 was added 10 min before this. D, quantitative comparison of the extent of glutamate release by 1 mM 4-AP in the absence and presence of 5 M pyridoxine and absence and presence of 10 M DL-TBOA, or 0.1 M bafilomycin A1. E, the release of FM1-43 was evoked by 1 mM 4-AP in the absence (control) or presence of 5 M pyridoxine. The numbers in parentheses indicate the number of experiments using independent synaptosomal preparations. Results are the mean Ϯ S.E.M. ‫,ء(‬ P Ͻ 0.01, two-tailed Student's t test; P Ͻ 0.05, ANOVA followed by two-tailed Student's t test). 
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Ca 2ϩ from internal stores is involved in the Ca 2ϩ influx coupled to glutamate release (Berridge, 1998 ). Thus, we tested the effect of dantrolene, an inhibitor of intracellular Ca 2ϩ release from endoplasmic reticulum, and CGP37157, a membrane-permeant blocker of mitochondrial Na ϩ /Ca 2ϩ exchange, on the pyridoxine inhibition of glutamate release. Dantrolene (100 M) reduced control 4-AP-evoked release from 7.6 Ϯ 0.1 to 5.5 Ϯ 0.1 nmol/mg/5 min. In the presence of dantrolene, however, pyridoxine (5 M) still effectively inhibited 4-AP-evoked glutamate release to 3.6 Ϯ 0.2 nmol/mg/5 min (n ϭ 6; P Ͻ 0.05; Fig. 5B ). Similarly to dantrolene, CGP37157 (100 M) decreased the release of glutamate evoked by 4-AP (1 mM), but it had a nonsignificant effect on the pyridoxine-mediated inhibition of 4-AP-evoked glutamate release (n ϭ 5; Fig. 5B ).
Pyridoxine-Mediated Inhibition of Glutamate Release Involves a PKC-Dependent Pathway. Because the PKC signaling cascade is known to be present at the presynaptic level and has a crucial role in neurotransmitter exocytosis (Coffey et al., 1993; Vaughan et al., 1998; Wang and Sihra, 2004) , we investigated whether the cascade participated in pyroxidine-mediated inhibition of glutamate release. To this end, we studied the effect of pyridoxine after inhibition of PKC. Figure 6A shows that PKC inhibitor GF109203X (1 M) reduced 1 mM 4-AP-evoked glutamate release from 7.7 Ϯ 0.1 to 3.9 Ϯ 0.3 nmol/mg/5 min, a substantial decrease (50.6 Ϯ 3.1% of control; Fig. 6B ), which indicated basal PKC activity. Addition of 5 M pyridoxine further reduced release to 3.7 Ϯ 0.3 nmol/mg/5 min. In the presence of GF109203X, therefore, pyridoxine induced a statistically insignificant inhibition of glutamate release of 5.1 Ϯ 2.1% compared with the 42.9 Ϯ 2.7% inhibition produced by pyridoxine alone. This inhibition of the effect of pyridoxine by GF109203X was also obtained with another PKC inhibitor, Ro318220. As with GF109203X, although Ro318220 (1 M) attenuated 4-AP-evoked glutamate release by 57.1 Ϯ 4.1% (3.3 Ϯ 0.4 nmol/mg/5 min; P Ͻ 0.01; two-tailed Student's t test), it also suppressed the inhibitory effect of (Fig. 6B) . In contrast to the effect of PKC inhibitors, the mitogen-activated protein (MAP) kinase inhibitor PD98059 failed to influence the ability of pyridoxine to inhibit 4-APevoked release of glutamate (Fig. 6B) .
To further confirm that the PKC signaling pathway was suppressed by pyridoxine during its inhibition of 4-AP-evoked glutamate release, we determined the effect of pyridoxine on the phosphorylation of PKC in cerebrocortical synaptosomes. Figure 7 shows that depolarization of synaptosomes with 1 mM 4-AP in the presence of 1.2 mM CaCl 2 increased the phosphorylation of PKC (137.7 Ϯ 2.1%; P Ͻ 0.01). When synaptosomes were pretreated with pyridoxine (5 M) for 10 min before depolarization with 1 mM 4-AP, 4-AP-enhanced phosphorylation of PKC was markedly decreased to 108.4 Ϯ 1.4% (P Ͻ 0.05; one-way repeated-measures ANOVA). Similar results were obtained from analysis of phosphorylation of PKC␣, a PKC isozyme that is found presynaptically in the cerebral cortex (Shearman et al., 1991) . Furthermore, we studied the effect of pyridoxine on the phosphorylation of MARCKS, a major presynaptic substrate for PKC. As shown in Fig. 7 , depolarization of synaptosomes with 4-AP (1 mM) increased the phosphorylation of MARCKS in the presence of external Ca 2ϩ (167.4 Ϯ 3.4%; P Ͻ 0.01), and this phenomenon was also reduced after pyridoxine (5 M) treatment (103.1 Ϯ 2.5%; n ϭ 5; P Ͻ 0.05).
Discussion
To the best of our knowledge, this study represents the first examination of the effect of pyridoxine on endogenous glutamate release at the presynaptic level. We have used a synaptosomal model to assess the characteristics and mechanism of inhibition of 4-AP-evoked glutamate release by pyridoxine in the cerebral cortex.
Glutamate release produced by the depolarization of isolated nerve terminals is known to have two components. The first is a physiologically relevant Ca 2ϩ -dependent component, which is produced by exocytosis of synaptic vesicles that contain glutamate. The second is a Ca 2ϩ -independent component that results from prolonged depolarization that causes a membrane-potential-mediated shift of the glutamate transporter steady state toward the outward direction to effect cytosolic glutamate efflux (Nicholls et al., 1987) . In the present study, the inhibition of 4-AP-evoked glutamate release attributable to the pyridoxine treatment was accounted for only by a reduction of the Ca 2ϩ -dependent, exocytotic component of glutamate release. This conclusion is based on the following observations. First, in the presence of Ca 2ϩ -free medium that contained BAPTA-AM, pyridoxine failed to inhibit significantly 4-AP-evoked glutamate release (Ca 2ϩ -independent release). Second, the inhibitory effect of pyridoxine on 4-AP-evoked glutamate release was effectively abolished by bafilomycin A1, which depletes the glutamate content of synaptic vesicles, but not by DL-TBOA, a nonselective inhibitor of all excitatory amino acid transporter subtypes. Third, by use of an exocytosis assay with FM1-43, inhibition of 4-AP-evoked FM1-43 release by pyridoxine was observed.
Inhibition of Ca 2ϩ -dependent glutamate release by pyridoxine could be ascribed to an alteration of plasma membrane potential, and/or a direct inhibition of the exocytosiscoupled Ca 2ϩ channel. Our demonstration, using the Ca 2ϩ indicator Fura-2, that the 4-AP-evoked increase in [Ca 2ϩ ] C was reduced by pyridoxine suggests that pyridoxine attenuates glutamate release by indirectly or directly reducing Ca 2ϩ influx into cerebrocortical nerve terminals. In synaptic terminals, a depolarization-induced increase in [Ca 2ϩ ] C , coupled to glutamate release, is mediated by extracellular Ca 2ϩ influx through VDCCs and intracellular store Ca 2ϩ release (Berridge, 1998) . Therefore, elucidating the mechanism of pyridoxine-reduced cytoplasmic Ca 2ϩ level is imperative. We examined whether Ca 2ϩ entry specifically through N-and P/Q-type VDCCs subserved the action of pyridoxine by assessing the effect of pyridoxine on glutamate release in the presence of Ca 2ϩ channel toxins. The inhibitory effect of pyridoxine on 4-AP-evoked glutamate release was prevented completely only under conditions in which all of the releasecoupled VDCCs were blocked. This indicates that pyridoxine effectively suppressed glutamate release components supported by N-and P/Q-type VDCCs. On the other hand, the participation of reduced release of stored Ca 2ϩ from the endoplasmic reticulum and mitochondria during the pyridoxine-mediated inhibition of glutamate release could be excluded. This was because the inhibitory effect of pyridoxine on 4-AP-evoked glutamate release was not affected by dantrolene, an inhibitor of intracellular Ca 2ϩ release from the endoplasmic reticulum, and CGP37157, a membrane-permeant blocker of mitochondrial Na ϩ /Ca 2ϩ exchange. The question remained as to whether the suppression of release-coupled VDCCs by pyridoxine reflected a direct effect on VDCC function. To address this issue, we compared the relative effects of pyridoxine on 4-AP-versus KCl-evoked activation of synaptosomal Ca 2ϩ entry. Both of these depolarizing treatments are thought to activate the release of P/Q-and N-type VDCCs coupled to glutamate similarly, and therefore, should reflect this by qualitatively similar modulation, if this occurs at the level of the VDCCs. The two depolarizing paradigms differ in that, whereas 4-AP-mediated depolarization/VDCC activation involves upstream K ϩ -and Na ϩ -channel activity, 15 mM external KCl affects experimental clamping of the K ϩ electrochemical potential, and hence, the membrane potential (Nicholls, 1998) . The latter type of depolarization bypasses regulation at the level of K ϩ channels and also effectively removes voltage-dependent Na ϩ involvement in that these channels are desensitized in response to strong and continued depolarization (Barrie et al., 1991) . Comparison of the two depolarizing agents revealed that 4-AP-and KCl-evoked VDCC activation was inhibited by pyridoxine. Moreover, the effect of pyridoxine on KCl-induced Ca 2ϩ influx was paralleled by the similar ability of pyridoxine to affect KCl-induced glutamate release. Based on the mechanistic differences between the 4-AP-and KClmediated depolarization discussed above, the results indicate that pyridoxine was able to inhibit glutamate release specifically and directly via the reducing activity of the VDCCs, rather than any upstream effect on nerve terminal excitability. This suggestion is supported by the observation that 4-AP-mediated depolarization, probed using the membranepotential-sensitive dye DiSC 3 (5), was unaffected by pyridoxine. Furthermore, pyridoxine did not affect the 4-AP-evoked Ca 2ϩ -independent glutamate release, a component of glutamate release that depends only on membrane potential (Attwell et al., 1993) .
PKC is an important intracellular signaling system that is known to be present at the presynaptic level, and has a crucial role in neurotransmitter exocytosis (Wang and Sihra, 2004; Pittaluga et al., 2005) . It has been shown that depolarization-stimulated Ca 2ϩ entry enhances PKC-dependent phosphorylation and glutamate release (Coffey et al., 1994) . Thus, it is reasonable to speculate that the inhibitory effect of pyridoxine on Ca 2ϩ entry observed here may decrease PKC activity and, in turn, glutamate release. In elucidating this, we found that: (1) the inhibitory effect of pyridoxine on 4-APevoked glutamate release was substantially prevented by PKC inhibitors; (2) pyridoxine significantly decreased 4-APinduced phosphorylation of PKC and PKC␣, an PKC isoform that is present presynaptically in the cerebral cortex (Shearman et al., 1991) ; and (3) 4-AP-induced phosphorylation of MARCKS, a major presynaptic substrate for PKC, was reduced by pyridoxine. These data suggest that an intracellular cascade involving the suppression of PKC-dependent pathways is linked to inhibition of 4-AP-evoked glutamate release by pyridoxine. Moreover, the inhibitory effect of pyridoxine on 4-APevoked glutamate release was not affected by the MAP kinase inhibitor, which demonstrated some specificity for pyridoxine action on the PKC pathway. In fact, PKC is capable of altering the phosphorylation state of a number of proteins involved in the synaptic vesicle trafficking/recruitment and exocytosis, including SNAP-25, synapsin I, and munc/nSecl (Jarvis and Zamponi, 2001; Craig et al., 2003) . Besides a participation of MARCKS in the inhibitory effect of pyridoxine on glutamate release, therefore, the possible involvement of other synaptic proteins should be considered. Overall, the main finding of the present study is that, in rat cerebrocortical nerve terminals, pyridoxine effects a decrease in the Ca 2ϩ influx through Nand P/Q-type Ca 2ϩ channels, which subsequently reduces the PKC/MARCKS phosphorylation to cause a decrease in evoked glutamate release (Fig. 8) .
The group of vitamin B 6 primarily consists of three interrelated vitamers including pyridoxine, pyridoxal, and pyridoxamine. All three pyrimidine derivatives are naturally existing forms of vitamin B 6 , which are converted to PLP in vivo (Wang et al., 2002) . From the previous report, it was clear that pyridoxal and PLP had protective effects against excitotoxicity besides pyridoxine (Geng et al., 1997; Dakshinamurti et al., 2003; Hwang et al., 2007) . In this study, an additional observation was that pyridoxal and PLP also dosedependently inhibited 4-AP-evoled glutamate release, with IC 50 values of 10 M for pyridoxal and 50 M for PLP (data not shown). Furthermore, inhibition of 4-AP-evoked glutamate release by pyridoxal and PLP was prevented in the combined blockade of N-and P/Q-type Ca 2ϩ channels (data not shown), consistent with the action of pyridoxine. Although PLP is the biologically active form of vitamin B 6 , pyridoxine was more effective than PLP in decreasing glutamate release in the present study. A plausible explanation for the differential effects of these compounds is that pyridoxine is superior to PLP in its penetration through cell jpet.aspetjournals.org membranes and, therefore, is more easily taken up by synaptosomes where it exerts actions. On the other hand, the concentration of pyridoxine used to inhibit glutamate release in our study in vitro (5 M) is lower than the common concentration of vitamin B 6 in the brain in vivo (8.9 M) (Spector and Johanson, 2007) . It has been shown that the administration of high-dose vitamin B 6 is associated with the development of neuropath (Helgren et al., 1997; Demir et al., 2005) ; the dose of pyridoxine we used, therefore, may be considered safe.
In human studies, low vitamin B 6 status has been reported to cause some pathological conditions such as ischemic stroke and seizures (Clayton, 2006) . As mentioned earlier, excessive release of glutamate that results in neuronal damage is a possible mechanism that underlies the pathophysiology of these diseases (Coyle and Puttfarcken, 1993; Meldrum, 2000) . The results described in this report demonstrate that pyridoxine inhibits glutamate release from cerebrocortical synaptosomes via a suppression of voltage-dependent Ca 2ϩ entry, supporting the hypothesis that vitamin B 6 may function as a potential source for brain therapeutics against excitotoxicity. Although the mechanisms of the neuroprotection conferred by vitamin B 6 are still under investigation, reducing glutamate release from nerve endings may explain the neuroprotective properties of vitamin B 6 in various models of neurotoxicity. The relevance of our finding to in vivo clinical situations remains to be determined. However, this finding may allow us to further understand the cellular mechanisms of action of vitamin B 6 in the central nervous system, and provides new avenues for the prevention, treatment, and drug development of a wide range of neurological and neurodegenerative disorders. 
